Amgen recommends against unsolicited mini-tender offer from TRC Capital
Amgen has been notified of an unsolicited "mini-tender" offer dated Oct. 11, made by TRC Capital, a private Canadian investment company, to purchase up to 500,000 shares of Amgen's common stock beginning on Oct. 14. TRC Capital's unsolicited "mini-tender" offer price of $192.00 per share is approximately 4.38% below the $200.80 per share closing price of Amgen's common stock on Oct. 11, the last trading day prior to the commencement of the offer. Amgen is not affiliated in any way with TRC Capital, the offer, or the offer documentation. Amgen recommends against shareholders tendering shares in response to this unsolicited offer. TRC Capital has made many similar "mini-tender" offers for the shares of other companies.